Pharmacological Properties of Shikonin – A Review of Literature since
                    2002

Isabel Andújar; José Luis Ríos; Rosa María Giner; María Carmen Recio

doi:10.1055/s-0033-1350934

Planta Medica, Inhaltsverzeichnis

Planta Med 2013; 79(18): 1685-1697
DOI: 10.1055/s-0033-1350934

Reviews

Georg Thieme Verlag KG Stuttgart · New York

Pharmacological Properties of Shikonin – A Review of Literature since 2002

Isabel Andújar

Departament de Farmacologia, Facultat de Farmàcia, Universitat de València, Valencia, Spain

,

José Luis Ríos

Departament de Farmacologia, Facultat de Farmàcia, Universitat de València, Valencia, Spain

,

Rosa María Giner

Departament de Farmacologia, Facultat de Farmàcia, Universitat de València, Valencia, Spain

,

María Carmen Recio

Departament de Farmacologia, Facultat de Farmàcia, Universitat de València, Valencia, Spain

› Institutsangaben

Abstract

The naphthoquinone shikonin is the main active principle of Zicao, a traditional Chinese herbal medicine made from the dried root of Lithospermum erythrorhizon. Studies carried out over the past 30 years have provided a scientific basis for the use of Zicao which has been long employed in folk medicine to treat a variety of inflammatory and infectious diseases. In particular, shikonin has been shown to possess many diverse properties, including antioxidant, anti-inflammatory, antithrombotic, antimicrobial, and wound healing effects. The fact that shikonin shows so many beneficial properties has increased the interest in this molecule dramatically, especially in the past few years. The aim of this review is to provide an update of the new data published on shikonin, whose wide spectrum of pharmacological effects as well as pharmacokinetic properties and toxicity make it a highly interesting target molecule.

Key words

anti-infectious - anti-inflammatory - antioxidant - glucose metabolism - wound healing - shikonin - Lithospermum erythrorhizon - Boraginaceae

Volltext

Referenzen

References
1 Chen X, Yang L, Oppenheim JJ, Howard OMZ. Cellular pharmacology studies of shikonin derivatives. Phytother Res 2002; 16: 199-209
2 Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D, Nicolaou KC. The chemistry and biology of alkannin, shikonin, and related naphthazarin natural products. Angew Chem Int Ed Engl 1999; 38: 270-301
3 Albreht A, Vovk I, Simonovska B. Addition of β-lactoglobulin produces water-soluble shikonin. J Agric Food Chem 2012; 60: 10834-10843
4 Papageorgiou VP, Assimopoulou AN, Ballis AC. Alkannins and shikonins: a new class of wound healing agents. Curr Med Chem 2008; 15: 3248-3267
5 Assimopoulou AN, Papageorgiou VP. Encapsulation of isohexenylnaphthazarins in cyclodextrins. Biomed Chromatogr 2004; 18: 240-247
6 Chen CY, Chen FA, Wu AB, Hsu HC, Kang JJ, Cheng HW. Effect of hydroxypropyl-β-cyclodextrin on the solubility, photostability and in vitro permeability of alkannin/shikonin enantiomers. Int J Pharm 1996; 141: 171-178
7 Xia H, Tang C, Gui H, Wang X, Qi J, Wang X, Yang Y. Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo . Biosci Rep 2013; 33: e00020
8 Assimopoulou AN, Papageorgiou VP, Kiparissides C. Synthesis and release studies of shikonin-containing microcapsules prepared by the solvent evaporation method. J Microencapsul 2003; 20: 581-596
9 Huang YI, Cheng YH, Yu CC, Tsai TR, Cham TM. Microencapsulation of extract containing shikonin using gelatin–acacia coacervation method: a formaldehyde-free approach. Colloids Surf B Biointerfaces 2007; 58: 290-297
10 Han J, Chen TX, Branford-White CJ, Zhu LM. Electrospun shikonin-loaded PCL/PTMC composite fiber mats with potential biomedical applications. Int J Pharm 2009; 382: 215-221
11 Kontogiannopoulos KN, Assimopoulou AN, Tsivintzelis I, Panayiotou C, Papageorgiou VP. Electrospun fiber mats containing shikonin and derivatives with potential biomedical applications. Int J Pharm 2011; 409: 216-228
12 Kontogiannopoulos KN, Assimopoulou AN, Hatziantoniou S, Karatasos K, Demetzos C, Papageorgiou VP. Chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology. Int J Pharm 2012; 422: 381-389
13 Kourounakis AP, Assimopoulou AN, Papageorgiou VP, Gavalas A, Kourounakis PN. Alkannin and shikonin: effect on free radical processes and on inflammation – a preliminary pharmacochemical investigation. Arch Pharm (Weinheim) 2002; 335: 262-266
14 Landa P, Kutil Z, Temml V, Vuorinen A, Malik J, Dvorkova M, Marsik P, Konoska L, Pribylova M, Schuster D, Vanek T. Redox and non-redox mechanism of in vitro cyclooxygenase inhibition by natural quinones. Planta Med 2012; 78: 326-333
15 Zeng YQ. Identificación y actividad farmacológica de principios de especies antiinflamatorias [PhD Thesis]. Valencia: University of Valencia; 2006
16 Kundakovic T, Fokialakis N, Dobric S, Pratsinis H, Kletsas D, Kovacevic N, Chinou I. Evaluation of the anti-inflammatory and cytotoxic activities of naphthazarine derivatives from Onosma leptantha . Phytomedicine 2006; 13: 290-294
17 Staniforth V, Wang SY, Shyur LF, Yang NS. Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor α promoter in vivo . J Biol Chem 2004; 279: 5877-5885
18 Andújar I, Recio MC, Bacelli T, Giner RM, Ríos JL. Shikonin reduces oedema induced by phorbol ester by interfering with IκBα degradation thus inhibiting translocation of NF-κB to the nucleus. Br J Pharm 2010; 160: 376-388
19 Cheng YW, Chang CY, Lin KL, Hu CM, Lin CH, Kang JJ. Shikonin derivatives inhibited LPS-induced NOS in RAW 264.7 cells via downregulation of MAPK/NF-κB signaling. J Ethnopharmacol 2008; 120: 264-271
20 Lu L, Qin A, Huang H, Zhou P, Zhang C, Liu N, Li S, Wen G, Zhang C, Dong W, Wang X, Dou QP, Liu J. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur J Pharmacol 2011; 658: 242-247
21 Dai Q, Fang J, Zhang FS. Dual role of shikonin in early and late stages of collagen type II arthritis. Mol Biol Rep 2009; 36: 1597-1604
22 Kim YO, Hong SJ, Yim SV. The efficacy of shikonin on cartilage protection in a mouse model of rheumatoid arthritis. Korean J Physiol Pharmacol 2010; 14: 199-204
23 Chakir H, Wang H, Lefebvre DE, Webb J, Scott FW. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 2003; 278: 157-169
24 Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 2012; 10: 82
25 Andújar I, Ríos JL, Giner RM, Cerdá-Nicolás M, Recio MC. Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice. Evid Based Complement Alternat Med 2012;
26 Takano-Ohmuro H, Yoshida LS, Yuda Y, Morioka K, Kitani S. Shikonin inhibits IgE-mediated histamine release by human basophils and Sky kinase activity. Inflamm Res 2008; 57: 484-488
27 Lee CC, Wang CN, Lai YT, Kang JJ, Liao JW, Chiang BL, Chen HC, Cheng YW. Shikonin inhibits maturation of bone marrow-derived dendritic cells and suppresses allergic airway inflammation in a murine model of asthma. Br J Pharmacol 2010; 161: 1496-1511
28 Lee CC, Kang JJ, Chiang BL, Wang CN, Cheng YW. Shikonin inhibited mitogen-activated IL-4 and IL-5 production on EL-4 cells through downregulation of GATA-3 and c-Maf induction. Life Sci 2011; 89: 364-370
29 Wang XC, Feng J, Huang F, Fan YS, Wang YY, Cao LY, Wen CP. Effects of shikonin isolated from zicao on lupus nephritis in NZB/W F1 mice. Biol Pharm Bull 2009; 32: 1565-1570
30 Xiong J, Ni J, Hu G, Shen J, Zhao Y, Yang L, Shen J, Yin G, Chen C, Yu G, Hu Y, Xing M, Wan R, Wang X. Shikonin ameliorates cerulein-induced acute pancreatitis in mice. J Ethnopharmacol 2013; 145: 573-580
31 Bai GZ, Yu HT, Ni YF, Li XF, Zhang ZP, Su K, Lei J, Liu BY, Ke CK, Zhong DX, Wang YJ, Zhao JB. Shikonin attenuates lipopolysaccharide-induced acute lung injury in mice. J Surg Res 2013; 182: 303-311
32 Chiu SC, Tsao SW, Hwang PI, Vanisree S, Chen YA, Yang NS. Differential functional genomic effects of anti-inflammatory phytocompounds on immune signaling. BMC Genomics 2010; 11: 513
33 Li T, Yan F, Wang R, Zhou H, Liu L. Shikonin suppresses human T lymphocyte activation through inhibition of IKKβ activity and JNK phosphorylation. Evid Based Complement Alternat Med 2013; 2013: 379536
34 Assimopoulou AN, Papageorgiou VP. Radical scavenging activity of Alkanna tinctoria root extracts and their main constituents, hydroxynaphthoquinones. Phytother Res 2005; 19: 141-147
35 Jin R, Bai Y. Theoretical investigation of the radical scavenging activity of shikonin and acylshikonin derivatives. J Mol Model 2012; 18: 1401-1408
36 Nishizawa M, Kohno M, Nishimura M, Kitagawa A, Niwano Y. Presence of peroxyradicals in cigarette smoke and the scavenging effect of shikonin, a naphthoquinone pigment. Chem Pharm Bull 2005; 53: 796-799
37 Wang Z, Liu T, Gan L, Wang T, Yuan X, Zhang B, Chen H, Zheng Q. Shikonin protects mouse brain against cerebral ischemia/reperfusion injury through its antioxidant activity. Eur J Pharmacol 2010; 643: 211-217
38 Nam KN, Son MS, Park JH, Lee EH. Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-κB: neuroprotective implications. Neuropharmacology 2008; 55: 819-825
39 Esmaeilzadeh E, Gardaneh M, Gharib E, Sabouni F. Shikonin protects dopaminergic cell line PC12 against 6-hydroxydopamine-mediated neurotoxicity via both glutathione-dependent and independent pathways and by inhibiting apoptosis. Neurochem Res 2013; 38: 1590-1604
40 Andrikopoulos NK, Kaliora AC, Assimopoulou AN, Papapeorgiou VP. Biological activity of some naturally occurring resins, gums and pigments against in vitro LDL oxidation. Phytother Res 2003; 17: 501-507
41 Yoshida LS, Kawada T, Irie K, Yuda Y, Himi T, Ikemoto F, Takano-Ohmuro H. Shikonin directly inhibits nitric oxide synthases: possible targets that affect thoracic aorta relaxation response and nitric oxide release from RAW 264.7 macrophages. J Pharmacol Sci 2010; 112: 343-351
42 Rajasekar S, Park da J, Park C, Park S, Park YH, Kim ST, Choi YH, Choi YW. In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanoma. J Ethnopharmacol 2012; 144: 335-345
43 Kretschmer N, Rinner B, Deutsch AJ, Lohberger B, Knausz H, Kunert O, Blunder M, Boechzelt H, Schaider H, Bauer R. Naphthoquinones from Onosma paniculata induce cell-cycle arrest and apoptosis in melanoma cells. J Nat Prod 2012; 75: 865-869
44 Min R, Zun Z, Min Y, Wenhu D, Wenjun Y, Chenping Z. Shikonin inhibits tumor invasion via down-regulation of NF-κB-mediated MMP-9 expression in human ACC-M cells. Oral Dis 2011; 17: 362-369
45 Yang H, Zhou P, Huang H, Chen D, Ma N, Cui QC, Shen S, Dong W, Zhang X, Lian W, Wang X, Dou QP, Liu J. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo . Int J Cancer 2009; 124: 2450-2459
46 Chang IC, Huang YJ, Chiang TI, Yeh CW, Hsu LS. Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells. Biol Pharm Bull 2010; 33: 816-824
47 Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011; 30: 4297-4306
48 Li W, Liu J, Zhao Y. PKM2 inhibitor Shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells. Mol Carcinogen 2012;
49 Yingkun N, Lvsong Z, Huimin Y. Shikonin inhibits the proliferation and induces the apoptosis of human HepG2 cells. Can J Physiol Pharmacol 2010; 88: 1138-1146
50 Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo J, Hu X. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007; 6: 1641-1649
51 Andújar I, Recio MD, Giner RM, Ríos JL. Traditional Chinese medicine remedy to jury: the pharmacological basis for the use of shikonin as an anticancer therapy. Curr Med Chem 2013; 20: 2892-2898
52 Huang C, Luo Y, Zhao J, Yang F, Zhao H, Fan W, Ge P. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS ONE 2013; 8: e66326
53 Piao JL, Cui ZG, Furusawa Y, Ahmed K, Rehman MU, Tambuchi Y, Kadowaki M, Kondo T. The molecular mechanisms and gene expression profiling for shikonin-induced apoptotic and necroptotic cell death in U937 cells. Chembiol Interact 2013;
54 Ahn J, Won M, Choi JH, Kim YS, Jung CR, Im DS, Kyun ML, Lee K, Song KB, Chung KS. Reactive oxygen species-mediated activation of the Akt/ASK1/p 38 signaling cascade and p 21(Cip1) downregulation are required for shikonin-induced apoptosis. Apoptosis 2013; 18: 870-881
55 Zhang B, Chen N, Chen H, Wang Z, Zheng Q. The critical role of redox homeostasis in shikonin-induced HL-60 cell differentiation via unique modulation of the Nrf2/ARE pathway. Oxid Med Cell Longev 2012; 2012: 781516
56 Wang H, Wu C, Wan S, Zhang H, Zhou S, Liu G. Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway. Toxicology 2013; 308: 104-112
57 Haghbeen K, Pourmolaei S, Mareftjo MJ, Mousavi A, Akbari Noghabi K, Hosseini Shirazi F, Meshkat A. Detailed investigations on the solid cell culture and antimicrobial activities of the Iranian Arnebia euchroma . J Biomed Biotechnol 2011; 2011: 165852
58 Ding X, Yin B, Qian L, Zeng Z, Yang Z, Li H, Lu Y, Zhou S. Screening for novel quorum-sensing inhibitors to interfere with the formation of Pseudomonas aeruginosa biofilm. J Med Microbiol 2011; 60: 1827-1834
59 Shen CC, Syu WJ, Li SY, Lin CH, Lee GH, Sun CM. Antimicrobial activities of naphthazarins from Arnebia euchroma . J Nat Prod 2002; 65: 1857-1862
60 Li HM, Tang YL, Zhang ZH, Liu CJ, Li HZ, Li RT, Xia XS. Compounds from Arnebia euchroma and their related anti-HCV and antibacterial activities. Planta Med 2012; 78: 39-45
61 Kuo HM, Hsia TC, Chuang YC, Lu HF, Lin SY, Chung JG. Shikonin inhibits the growth and N-acetylation of 2-aminofluorene in Helicobacter pylori from ulcer patients. Anticancer Res 2004; 24: 1587-1592
62 Sasaki K, Abe H, Yoshizaki F. In vitro antifungal activity of naphthoquinone derivatives. Biol Pharm Bull 2002; 25: 669-670
63 Miao H, Zhao L, Li C, Shang Q, Lu H, Fu Z, Wang L, Jiang Y, Cao Y. Inhibitory effect of shikonin on Candida albicans growth. Biol Pharm Bull 2012; 35: 1956-1963
64 Michaelakis A, Strongilos AT, Bouzas EA, Koliopoulos G, Couladouros EA. Larvicidal activity of naturally occurring naphthoquinones and derivatives against the West Nile virus vector Culex pipiens . Parasitol Res 2009; 104: 657-662
65 Ali A, Assimopoulou AN, Papageorgiou VP, Kolodziej H. Structure/antileishmanial activity relationship study of naphthoquinones and dependency of the mode of action on the substitution patterns. Planta Med 2011; 77: 2003-2012
66 Chen X, Yang L, Zhang N, Turpin JA, Buckheit RW, Osterling C, Oppenheim JJ, Howard OM. Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother 2003; 47: 2810-2816
67 Min BS, Miyashiro H, Hattori M. Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother Res 2002; 16: S57-S62
68 Gao H, Liu L, Qu ZY, Wei FX, Wang SQ, Chen G, Qin L, Jiang FY, Wang YC, Shang L, Gao CY. Anti-adenovirus activities of shikonin, a component of Chinese herbal medicine in vitro . Biol Pharm Bull 2011; 34: 197-202
69 Karayannopoulou M, Tsioli V, Loukopoulos P, Anagnostou TL, Giannakas N, Savvas I, Papazoglou LG, Kaldrymidou E. Evaluation of the effectiveness of an ointment based on Alkannins/Shikonins on second intention wound healing in the dog. Can J Vet Res 2011; 75: 42-48
70 Hsiao CY, Tsai TH, Chak KF. The molecular basis of wound healing processes induced by Lithospermi Radix: a proteomics and biochemical analysis. Evid Based Complement Alternat Med 2012;
71 Andújar I, Ríos JL, Giner RM, Recio MC. Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cells. Eur J Pharm Sci 2013; 49: 637-641
72 Gwon SY, Ahn JY, Chung CH, Moon BK, Ha TY. Lithospermum erythrorhizon suppresses high-fat diet-induced obesity, and acetylshikonin, a main compound of Lithospermum erythrorhizon, inhibits adipocyte differentiation. J Agric Food Chem 2012; 60: 9089-9096
73 Lee H, Kang R, Yoon Y. Shikonin inhibits fat accumulation in 3 T3-L1 adipocytes. Phytother Res 2010; 24: 344-351
74 Lee H, Bae S, Kim K, Kim W, Chung SI, Yang Y, Yoon Y. Shikonin inhibits adipogenesis by modulation of the WNT/β-catenin pathway. Life Sci 2011; 88: 294-301
75 Kamei R, Kitagawa Y, Kadokura M, Hattori F, Hazeki O, Ebina Y, Nishihara T, Oikawa S. Shikonin stimulates glucose uptake in 3 T3-L1 adipocytes via an insulin-independent tyrosine kinase pathway. Biochem Biophys Res Commun 2002; 292: 642-651
76 Nigorikawa K, Yoshikawa K, Sasaki T, Iida E, Tsukamoto M, Murakami H, Maehama T, Hazeki K, Hazeki O. A naphthoquinone derivative, shikonin, has insulin-like actions by inhibiting both phosphatase and tensin homolog deleted on chromosome 10 and tyrosine phosphatases. Mol Pharmacol 2006; 70: 1143-1149
77 Öberg AI, Yassin K, Csikasz RI, Dehvari N, Shabalina IG, Hutchinson DS, Wilcke M, Östenson CG, Bengtsson T. Shikonin increases glucose uptake in skeletal muscle cells and improves plasma glucose levels in diabetic Goto-Kakizaki rats. PLoS One 2011; 6: e22510